Search
tolcapone (Tasmar)
Indications:
- adjunct agent used with Sinemet for treatment of Parkinson's disease with sign/symptoms of end of dose "wearing off"
- parkinsonism
Dosage:
1) start 100 mg PO QD
2) increase to 100-200 mg PO TID
3) keep 1st daily L-dopa dose the same
4) generally decreases total L-dopa dose by 20-30% [2]
Pharmacokinetics:
1) bioavailability is 10-20%
2) protein binding > 99%
3) elimination 1/2life is 2-3 hours
Monitor:
- liver function tests every 2 weeks for the 1st year, monthly for the next 6 months, every 2 months thereafter [3]
Adverse effects:
1) fulminant hepatotoxicity associated with death
a) 3 deaths reported as of 2004
b) risk is < 1 in 20,000
2) other
- dyskinesia, nausea, sleep disorder, dystonia, anorexia, muscle cramps, orthostasis, somnolence, diarrhea, confusion, dizziness, headache, hallucinations, vomiting, constipation, fatigue, upper respiratory tract infection, falls, sweating, urinary tract infection, xerostomia, abdominal pain, urine discoloration
Drug interactions:
1) avoid non-selective MAO inhibitors (selegiline, MAO-B inhibitor is OK)
2) drugs metabolized by COMT
- isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alpha-methyldopa, apomorphine, isoetharine, bitolterol
Mechanism of action:
1) inhibits catechol-O-methyltransferase
2) decreases L-dopa clearance
3) both peripheral & central actions
4) more potent than entacapone
General
enzyme inhibitor
pharmacologic agents for treatment of Parkinson's disease
Properties
INHIBITS: catechol O-methyl transferase
Database Correlations
PUBCHEM correlations
References
- Kaiser Permanente Pharmacy update
- Bronstein J, In: Intensive Course in Geriatric Medicine &
Board Review, Marina Del Ray, CA, Sept 29-Oct 2, 2004
- Prescriber's Letter 17(7): 2010
Recommended Lab Monitoring for Common Medications
Liver Function Test Scheduling
Detail-Document#: 260704
(subscription needed) http://www.prescribersletter.com